TEVOGEN Aktie

 

WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stock to the Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235....

Tevogen honors Board Member Dr. Curtis Patton as Yale recognizes his distinguished career, underscoring the Company's ongoing growth....

WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey's economic and innovation landscape....

Tevogen Bio highlights continued capital-efficient execution at a time when sustainability has become a defining challenge for the biotechnology industry....

WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a clinical milestone in the evolution of its proprietary ExacTcell™ platform: completion of T cell target identification for an additional five human leukocyte antigen (HLA) restrictions. This advancement significantly broadens the accessibility of Tevogen's investigational precision T cell therapies by extending therapeutic reach beyond the single HLA-A*02:01 restriction used in the Company's initial proof-of-concept (POC) clinical trial, the results of which were published in Blood Advances. That study demonstrated the safety and feasibility of Tevogen's third-party cytotoxic T lymphocyte (CTL) therapy, TVGN 489, in high-risk patients with COVID-19....

Tevogen clarifies GAAP-reported deficit, citing strong capital efficiency, low cash burn, and plans to share reconciled non-GAAP metrics....

WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company's significant progress toward making precision medicine accessible to all....

WARREN, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued an update regarding growing public interest in its investigational precision T cell therapy, TVGN 489, under development for COVID-19 and Long COVID....

WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision immunotherapy development and efficacy through advanced machine learning and transformer-based models. The platform is being developed with the support of Microsoft (Nasdaq: MSFT) and Databricks, leveraging their advanced cloud and data technologies to enable scalability and efficiency....

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need....

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research....

WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025....

WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections....

WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with evidence of a persistent viral reservoir....

WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV)....

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company's investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to fortify anti-SARS-CoV-2 immunity in these individuals and directly eliminate the virus. The CTLs are directed against the entire viral genome rather than single protein. Publication of positive POC/dose finding clinical trial data of TVGN 489 is available through Blood Advances:...

WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company's balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days....

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH '95, and the Company's mission of health equity....

WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC)....

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio's Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma....